CSIMarket
 
Sio Gene Therapies Inc   (SIOX)
Other Ticker:  
 
 
Price: $0.4780 $0.01 1.702%
Day's High: $0.478 Week Perf: 25.79 %
Day's Low: $ 0.45 30 Day Perf: 24.16 %
Volume (M): 40 52 Wk High: $ 0.50
Volume (M$): $ 19 52 Wk Avg: $0.40
Open: $0.45 52 Wk Low: $0.25



 Market Capitalization (Millions $) 35
 Shares Outstanding (Millions) 74
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) -37
 Capital Exp. (TTM) (Millions $) 1

Sio Gene Therapies Inc
Sio Gene Therapies Inc is a gene therapy company focused on developing, manufacturing, and delivering transformative gene therapies for patients with neurological disorders. The company aims to address the root cause of these disorders by utilizing their proprietary technology platform to deliver gene therapies directly to the brain.

Sio Gene Therapies Inc is committed to advancing gene therapy as a treatment modality through their innovative approach to target the underlying genetic mutations and restore normal gene expression. They have an extensive pipeline of gene therapy candidates aimed at treating various neurological disorders including genetic disorders, neurodegenerative diseases, and rare monogenic conditions.

The company's mission is to bring hope to patients and their families by providing effective and durable treatments for debilitating neurological disorders. They strive to leverage their expertise in gene therapy development and manufacturing to accelerate the development of novel therapies and improve the quality of life for patients.


   Company Address: 1501 Broadway New York 10036 NY
   Company Phone Number: 677-6770   Stock Exchange / Ticker: NASDAQ SIOX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Ani Pharmaceuticals Inc

2. Embracing Success: ANI Pharmaceuticals Inc's Remarkable Turnaround in Q4 2023

As a pharmaceutical industry enthusiast and an avid follower of ANI Pharmaceuticals Inc, I am thrilled to report on the recent financial results and business highlights of this major pharmaceutical preparations company. The October to December 31, 2023 fiscal time-frame has proven to be a turning point for ANI Pharmaceuticals Inc, as they have witnessed significant improvements in their earnings and revenue.
Starting with earnings per share, ANI Pharmaceuticals Inc saw a substantial positive shift from $-0.23 a year prior to $0.03 per share in the recent fiscal time-frame. This impressive improvement showcases the company's ability to effectively manage their financial performance and generate profits. Additionally, ANI Pharmaceuticals Inc reported earnings per share of $0.85 compared to $-3.05 in the previous fiscal year, indicating remarkable growth.

Chimerix Inc

Serious headline: Chimerix Inc Sees Decrease in Losses During Fourth Quarter of 2023

Chimerix Inc, a major pharmaceutical preparations company, experienced a decrease in their loss per share for the October to December 31, 2023 interval. The loss per share decreased from $-0.22 to $-0.20 compared to the same period the previous year. Additionally, their income per share improved from $-0.27 to -$0.20 from the prior quarter.
However, the company witnessed a sharp decline in revenue during this interval. The revenue dropped from $0.81 million in the same quarter the previous year to $0.00 million, and sequentially from $0.01 million.

Compass Pathways Plc

Compass Pathways Plc Reports Impressive Fourth Quarter Efforts Amidst Industry Growth

Compass Pathways Plc, a biotechnology company focused on mental health innovation, has experienced significant growth in its share price over the past year. According to recent financial results, the company's shares have risen by 24.72% compared to a year ago, reaching an impressive 69.55% increase in the past 90 days alone. This positive trend is further supported by the fact that Compass Pathways Plc shares are currently trading on the NASDAQ at a significant 22.4% above its 52-week average.
One factor that could potentially contribute to this growth is the company's collaboration with Hackensack Meridian Health (HMH) to optimize the clinical model for COMP360 psilocybin treatment, a psychedelic substance found in magic mushrooms. This collaboration aims to develop an effective treatment model if approved by the FDA, highlighting Compass Pathways' commitment to innovative mental health solutions.

Verona Pharma Plc

Lackluster revenue at the Verona Pharma Plc amid the financial interval closing December 31 2023

Verona Pharma Plc, a prominent player in the pharmaceutical industry, has recently made strategic moves to strengthen its financial position, enabling continued growth. Despite a minor increase in borrowings, the company has successfully enhanced its Leverage Ratio, surpassing its own average and outperforming 16 competitors within the industry. These developments have significant implications for the company's overall trajectory.
Verona Pharma Plc has managed to boost its Leverage Ratio to 0.11 in the third quarter of 2023. This ratio exceeds the company's typical average and ranks higher than its Leverage Ratio in the previous quarter. What makes this achievement even more noteworthy is that 16 other companies in the industry reported lower Leverage Ratios during the same period, highlighting Verona Pharma's superior financial standing.

Moonlake Immunotherapeutics

The Major Pharmaceutical Preparations company caused good story for the shareholders, presenting an important gain in financial time-frame ending December 31 2023 with operating loss of $-15.028897 million

Moonlake Immunotherapeutics is a small pharmaceutical company that has been making headlines in the Major Pharmaceutical Preparations sector with its latest financial performance. The company has shown significant improvement in its operating loss, decreasing from $-29.927 million in the fourth quarter of 2022 to $-15.028897 million in the same period of 2023. This is a positive sign for Moonlake Immunotherapeutics as it demonstrates a strong commitment to cost-effectiveness and financial stability.
One of the key indicators of Moonlake Immunotherapeutics' potential for growth is the decrease in diminishing returns, which have declined to $-7.887 million in the fourth quarter of 2023 from $-29.644 million in the previous year. This trend suggests that the company is on the right path to becoming a major player in the Healthcare sector. Additionally, the increase in accounts receivable is a promising sign of rising demand for Moonlake Immunotherapeutics' products and services.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com